CORSEARCH
23.5.2024 14:44:27 CEST | Business Wire | Press release
Corsearch, the leading provider of brand protection and trademark solutions, has today shared research forecasting that the number of active global trademarks will surpass the 100 million mark by 2026, in just two years.
Data from the Corsearch TrademarkNow platform shows that there were 83,613,385 active trademarks at the end of 2023, predicted to rise to 88,072,867 by the end of this year. Corsearch calculations forecast that by 2026, this figure will reach 100,720,928 – an increase of over 150% from the 2016 figures from a decade prior.
This growth in active trademark volumes demonstrates the increasing number of intellectual properties being developed and used by organizations across the world, in addition to a growing focus on the importance of protecting your intangible assets.
Examining 2024 filing figures, Corsearch can reveal that the country with the most active companies filing trademarks is China, followed swiftly by the USA and Brazil. The UK ranks 8th globally and, of the EU, only France features in the top ten most active filing countries.
Trademark volume rankings by originating country, 2023 |
|
1. |
China |
2. |
USA |
3. |
Brazil |
4. |
India |
5. |
Turkey |
6. |
Mexico |
7. |
Japan |
8. |
United Kingdom |
9. |
Russia |
10. |
France |
In order to support in-house counsel and expert IP advisors through this period of significant growth, Corsearch has also today announced its next-generation TrademarkNow platform. Lightning-fast AI and insights from 1,000+ sources ensure comprehensive trademark searching and monitoring – upgrades include:
- 75% faster turnaround time for notices than other industry solutions. Automated and Expert Watch solutions offer options between AI technology to deliver efficient monitoring of trademarks in the face of expanding trademark portfolios without sacrificing accuracy, or bespoke strategies and focused insights for more complex, high-value matters
- 40% improvement in IP legal team speeds of delivery for brand name clearance, with Corsearch LogoCheck and Name Generator tools allowing better searching of existing brand identities in combination with AI suggestions of candidate names
- Industrial Designs can be searched faster and more accurately through new similarity algorithms and the Corsearch AI image recognition engine
- ExaMatch search modifiers and NameCheck reporting allow for more targeted search queries and customizable reports better fit for individual needs
Viji Krishnan, President of Trademark Solutions, Corsearch, commented:
“Over the past years, the world has been waking up to the importance of trademarking intangible assets and intellectual property, and the risks of not doing so. It’s no surprise that we are only a few years away from seeing over 100 million trademarks active across the globe. It’s an optimistic sign of the intense innovation fuelling global organizations and empowering global business.
“But as with most things: the higher the volume of actively registered trademarks, the greater the potential complexity for IP professionals. We’re delighted to be launching our next-generation TrademarkNow platform to help experts in our sector cut through the noise. New AI tools will operate at the sheer scale needed to manage the size of modern trademark portfolios, effective dashboards which help prioritize work and the combined human expertise of our analysts who average over 15 years’ experience, ensures that brands uphold trademark distinctiveness.”
Notes to Editors
Methodology
Corsearch calculations are based on the data sourced from the TrademarkNow™ global trademark platform spanning all global trademark offices and registries. Where applicable, the effects of COVID on trademark filing have been accounted for.
About Corsearch:
Corsearch’s leading Trademark and Brand & Content Protection Solutions are revolutionizing how companies create, monitor, and protect their brands. Over 5,000 businesses worldwide partner with Corsearch to safeguard consumers and their trust in brands — preventing confusion, misrepresentation, and fraud using the hybrid intelligence of advanced AI precision and expert decision of human analysts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521172877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
